Alkermes | Sustainability Performance
Alkermes, Inc. develops pharmaceutical products addressing central nervous system disorders and other chronic diseases through innovative therapies.
1987
Ireland
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7673
Overallⓘ#50
in Irelandⓘ#166
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Alkermes paid USD 1.6 million SEC settlement over inadequate disclosure of clinical trial results, plus faced sustained scrutiny over Vivitrol opioidaddiction treatment pricing and Medicaid rebate disputes.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.